Login to Your Account

Kosan Drops Offering On 'Perceived' Clinical Threat

By Karen Pihl-Carey

Wednesday, August 17, 2005
Following a 17 percent stock slide Monday after the National Cancer Institute announced plans to amend the clinical trial protocols for 17-AAG and KOS-1022, Kosan Biosciences Inc. terminated its $39.4 million public offering priced just last week. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription